Short progression‐free survival of ALK inhibitors sensitive to secondary mutations in ALK‐positive NSCLC patients

BACKGROUND: Most non‐small cell lung cancer (NSCLC) patients relapse on anaplastic lymphoma kinase‐tyrosine kinase inhibitor (ALK‐TKI) therapy because of acquired resistance. Rebiopsy is recommended to provide optimal therapy after relapse for some ALK‐TKI therapies; however, little clinical data ex...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Thorac Cancer
Main Authors: Haratake, Naoki, Seto, Takashi, Takamori, Shinkichi, Toyozawa, Ryo, Nosaki, Kaname, Miura, Naoko, Ohba, Taro, Toyokawa, Gouji, Taguchi, Kenichi, Yamaguchi, Masafumi, Shimokawa, Mototsugu, Takenoyama, Mitsuhiro
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons Australia, Ltd 2019
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6718030/
https://ncbi.nlm.nih.gov/pubmed/31338990
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13143
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados